Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Helen of Troy Q4

This article was originally published in The Rose Sheet

Executive Summary

Acquisitions of cosmetic brands will "aggressively" be pursued over the next few years to build firm's liquid cosmetics category to $200 mil. business, CEO and President Gerald Rubin says during May 13 analyst call. Net sales in Q4 were up 22% to $89.7 mil. (excluding Tactica depilatory brands) on the strength of six brands acquired from P&G during the third quarter, including Final Net hair spray, Condition 3-in-1 and Sea Breeze skin care products, firm says in May 13 1press release. Including Tactica business, net sales were nearly flat at $102.3 mil. Consolidated earnings during the quarter (ended Feb. 28) soared 48.3% to $6.5 mil...

You may also be interested in...



Helen Of Troy Adding Muscle To Men’s Business With Brut

Helen of Troy will expand its portfolio into the male fragrance and antiperspirant/deodorant categories with the purchase of Unilever's Brut brand, the El Paso, Texas firm reported Sept. 2

Helen of Troy

Thomas Benson appointed senior VP, CFO, El Paso, Texas personal care company reports Aug. 19. Benson joins the company from Elamex, where he worked in a similar capacity as VP and CFO since July 2002. Firm, which recently purchased Final Net hair spray, Condition 3-in-1 and Sea Breeze skin care from Procter & Gamble is pursuing cosmetics acquisitions (1"The Rose Sheet" May 19, 2003, In Brief)...

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011210

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel